natgillin/translations-raw huggingface dataset:
Reduktionen i kropsvægt ved en kombination af sitagliptin og metformin var den samme som den, der blev observeret med metformin alene eller placebo. 
The decrease in body weight with the combination of sitagliptin and metformin was similar to that observed with metformin alone or placebo; there was no change from baseline for patients on sitagliptin alone.
Tel: +39 06 361911 doccen@merck.com 
Tel: +39 06 361911 medicalinformation.it@merck.com
Behandling med Ristfor skal afbrydes på tidspunktet for kirurgi under generel, spinal eller epidural anæstesi og må tidligst genoptages 48 timer efter kirurgi eller genoptagelse af oral ernæring og under forudsætning af, at nyrefunktionen er blevet vurderet og fundet stabil. 
Therapy may be restarted no earlier than 48 hours following surgery or resumption of oral nutrition and provided that renal function has been re-evaluated and found to be stable.
Der er ingen klinisk erfaring fra patienter med svær leverinsufficiens (ChildPugh score >9), men da sitagliptin primært elimineres renalt, forventes svær leverinsufficiens ikke at påvirke sitagliptins farmakokinetik. 
However, because sitagliptin is primarily renally eliminated, severe hepatic impairment is not expected to affect the pharmacokinetics of sitagliptin.
Nyrefunktionen 
Renal function
Desuden indeholder filmovertrækket: Poly(vinylalkohol), macrogol 3350, talcum (E553b), titandioxid (E171), rød jernoxid ((E172) og sort jernoxid (E172). 
In addition, the film coating contains: poly(vinyl alcohol), macrogol 3350, talc (E553b), titanium dioxide (E171), iron oxide red (E172), and iron oxide black (E172).
Undersøgelse af sitagliptin i kombination med metformin og insulin En 24-ugers placebokontrolleret undersøgelse blev designet til at evaluere effekt og sikkerhed af sitagliptin (100 mg en gang dagligt) som supplement til insulin (ved stabil dosis i mindst 10 uger) med eller uden metformin (mindst 1500 mg). 
Study of sitagliptin in combination with metformin and insulin A 24-week placebo-controlled study was designed to evaluate the efficacy and safety of sitagliptin (100 mg once daily) added to insulin (at a stable dose for at least 10 weeks) with or without metformin (at least 1,500 mg).
Mave-tarm-kanalen Diarré 
Gastrointestinal disorders diarrhoea
Incidensen af hypoglykæmi hos patienter, der blev behandlet med sitagliptin, var den samme som for placebo. 
The observed incidence of hypoglycaemia in patients treated with sitagliptin was similar to placebo.
Det gennemsnitlige fordelingsvolumen ved steady state efter en enkelt intravenøs dosis på 100 mg sitagliptin til raske forsøgspersoner er ca. 198 l. Den fraktion af sitagliptin, som er reversibelt bundet til plasmaproteiner, er lav (38%). 
The mean volume of distribution at steady state following a single 100-mg intravenous dose of sitagliptin to healthy subjects is approximately 198 litres.
Patienterne fik sitagliptin (7.332) 100 mg dagligt (eller 50 mg dagligt, hvis eGFR ved baseline var ≥ 30 og < 50 ml/min/1,73 m2) eller placebo (7.339) som supplement til standardbehandling målrettet de regionale standarder for HbA1c og kardiovaskulære risikofaktorer. 
The TECOS was a randomised study in 14,671 patients in the intention-to-treat population with an HbA1c of ≥ 6.5 to 8.0 % with established CV disease who received sitagliptin (7,332) 100 mg daily (or 50 mg daily if the baseline eGFR was ≥ 30 and < 50 mL/min/1.73 m2) or placebo (7,339) added to usual care targeting regional standards for HbA1c and CV risk factors.
Undersøgelse af sitagliptin i kombination med metformin og en PPAR-agonist Et 26-ugers placebokontrolleret studie blev designet til at evaluere sitagliptins effekt og sikkerhed (100 mg en gang dagligt) som supplement til kombinationen pioglitazon plus metformin. 
Study of sitagliptin in combination with metformin and a PPAR agonist A 26-week placebo-controlled study was designed to evaluate the efficacy and safety of sitagliptin (100 mg once daily) added to the combination of pioglitazone and metformin.
Patienterne skal informeres om at stoppe med at tage metformin og øjeblikkeligt søge lægehjælp ved symptomer, der kan give mistanke om laktacidose. 
In case of suspected symptoms, the patient should stop taking metformin and seek immediate medical attention.
Sitagliptin 100 mg en gang dagligt som supplement til igangværende insulin- + metforminbehandling (N=223) 
Sitagliptin 100 mg once daily added to ongoing insulin + metformin therapy (N=223)
Undersøgelse af sitagliptin i kombination med metformin og et sulfonylurinstof En 24-ugers placebokontrolleret undersøgelse blev designet til at vurdere effekt og sikkerhed af sitagliptin (100 mg en gang dagligt) som supplement til glimepirid (alene eller i kombination med metformin). 
Study of sitagliptin in combination with metformin and a sulphonylurea A 24-week placebo-controlled study was designed to evaluate the efficacy and safety of sitagliptin (100 mg once daily) added to glimepiride (alone or in combination with metformin).
Nogle af disse tyder på neural toksicitet: Vejrtrækning med åben mund, spytafsondring, hvid skummende opkastning, ataksi, skælven, nedsat aktivitet og/eller krum stilling. 
Transient treatment-related physical signs, some of which suggest neural toxicity, such as open-mouth breathing, salivation, white foamy emesis, ataxia, trembling, decreased activity, and/or hunched posture were observed in dogs at exposure levels approximately 23 times the clinical exposure level.
Til patienter, der ikke er tilstrækkeligt kontrolleret på metformin alene, bør den normale startdosis doseres som 50 mg sitagliptin to gange dagligt (100 mg i alt pr. dag) plus den dosis metformin, som allerede tages. 
For patients inadequately controlled on maximal tolerated dose of metformin monotherapy For patients not adequately controlled on metformin alone, the usual starting dose should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) plus the dose of metformin already being taken.
hæmmere). 
(pancreatitis).
Den maksimale daglige dosis er 25 mg. 
Maximum daily dose is 25 mg.
Peak-plasmakoncentrationer (median Tmax) forekom 1-4 timer efter dosering, gennemsnitlig plasmaAUC for sitagliptin var 8,52 µM•hr, Cmax var 950 nM. Sitagliptins absolutte biotilgængelighed er ca. 87%. 
Following oral administration of a 100-mg dose to healthy subjects, sitagliptin was rapidly absorbed, with peak plasma concentrations (median Tmax) occurring 1 to 4 hours post-dose, mean plasma AUC of sitagliptin was 8.52 M•hr, Cmax was 950 nM.
Ristfor 50 mg/850 mg filmovertrukne tabletter. 
Ristfor 50 mg/850 mg film-coated tablets
Den maksimale daglige dosis er 100 mg. 
Maximum daily dose is 100 mg.
Analyse af resultaterne for overvægtige patienter, der blev behandlet med metformin efter svigt af diæt alene, viste: - signifikant reduktion af den absolutte risiko for diabetesrelaterede komplikationer i metformingruppen (29,8 hændelser/1.000 patientår) versus diæt alene (43,3 hændelser/1.000 patientår), p=0,0023, og versus den kombinerede sulfonylurinstof/insulinmonoterapigruppe (40,1 hændelser/1.000 patientår), p=0,0034. 
Analysis of the results for overweight patients treated with metformin after failure of diet alone showed: - a significant reduction of the absolute risk of any diabetes-related complication in the metformin group (29.8 events/1,000 patient-years) versus diet alone (43.3 events/1,000 patient-years), p=0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/1,000 patient-years), p=0.0034 - a significant reduction of the absolute risk of any diabetes-related mortality: metformin 7.5 events/1,000 patient-years, diet alone 12.7 events/1,000 patient-years, p=0.017 - a significant reduction of the absolute risk of overall mortality: metformin 13.5 events/1,000 patient-years versus diet alone 20.6 events/1,000 patient-years, (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups 18.9 events/1,000 patient-years (p=0.021) - a significant reduction in the absolute risk of myocardial infarction: metformin 11 events/1,000 patient-years, diet alone 18 events/1,000 patient-years, (p=0.01).
Absolut biotilgængelighed for en 500 mg metformintablet er ca. 50-60% hos raske forsøgspersoner. 
After an oral dose of metformin, Tmax is reached in 2.5 h. Absolute bioavailability of a 500 mg metformin tablet is approximately 50-60 % in healthy subjects.
Sitagliptin 100 mg en gang dagligt som supplement til igangværende behandling med pioglitazon + metformin (N=152) 
Sitagliptin 100 mg once daily added to ongoing pioglitazone + metformin therapy (N=152)
Den maksimale daglige dosis er 50 mg. 
Maximum daily dose is 50 mg.
Ristfor er indiceret som supplement til diæt og motion i kombination med et sulfonylurinstof (dvs. tripel kombinationsbehandling) hos patienter, der ikke er tilstrækkeligt kontrolleret på den maksimalt tolererede dosis metformin og sulfonylurinstof. 
Ristfor is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
- Hvis De har en alvorlig infektion eller har væskemangel. 
- if you have a severe infection or are dehydrated - if you are going to have an X-ray where you will be injected with a dye.
Ristfor 50 mg/1.000 mg filmovertrukne tabletter. 
Ristfor 50 mg/1,000 mg film-coated tablets
Den maksimale daglige dosis er 3.000 mg. 
Maximum daily dose is 3000 mg.
Sitagliptin 100 mg en gang dagligt som supplement til metforminbehandling (N=453) 
Sitagliptin 100 mg once daily added to ongoing metformin therapy (N=453)
EU/1/10/620/009 14 filmovertrukne tabletter EU/1/10/620/010 28 filmovertrukne tabletter EU/1/10/620/011 56 filmovertrukne tabletter EU/1/10/620/021 60 filmovertrukne tabletter EU/1/10/620/012 112 filmovertrukne tabletter EU/1/10/620/013 168 filmovertrukne tabletter EU/1/10/620/022 180 filmovertrukne tabletter EU/1/10/620/014 196 filmovertrukne tabletter EU/1/10/620/015 50 x 1 filmovertrukne tabletter EU/1/10/620/016 196 (2 x 98) filmovertrukne tabletter EU/1/10/620/018 168 (2 x 84) filmovertrukne tabletter 
EU/1/10/620/009 14 film-coated tablets EU/1/10/620/010 28 film-coated tablets EU/1/10/620/011 56 film-coated tablets EU/1/10/620/021 60 film-coated tablets EU/1/10/620/012 112 film-coated tablets EU/1/10/620/013 168 film-coated tablets EU/1/10/620/022 180 film-coated tablets EU/1/10/620/014 196 film-coated tablets EU/1/10/620/015 50 x 1 film-coated tablets EU/1/10/620/016 196 (2 x 98) film-coated tablets EU/1/10/620/018 168 (2 x 84) film-coated tablets
Den maksimale daglige dosis er 2.000 mg. 
Maximum daily dose is 2000 mg.
- Lægen har ordineret Ristfor til Dem personligt. 
- This medicine has been prescribed for you only.
: Sitagliptin 50 mg + metformin 500 mg (N=183) Initialbehandling (to gange dagligt) 
Sitagliptin 50 mg + metformin 500 mg (N=183)
EU/1/10/620/001 14 filmovertrukne tabletter EU/1/10/620/002 28 filmovertrukne tabletter EU/1/10/620/003 56 filmovertrukne tabletter EU/1/10/620/019 60 filmovertrukne tabletter EU/1/10/620/004 112 filmovertrukne tabletter EU/1/10/620/005 168 filmovertrukne tabletter EU/1/10/620/020 180 filmovertrukne tabletter EU/1/10/620/006 196 filmovertrukne tabletter EU/1/10/620/007 50 x 1 filmovertrukne tabletter EU/1/10/620/008 196 (2 x 98) filmovertrukne tabletter EU/1/10/620/017 168 (2 x 84) filmovertrukne tabletter 
EU/1/10/620/001 14 film-coated tablets EU/1/10/620/002 28 film-coated tablets EU/1/10/620/003 56 film-coated tablets EU/1/10/620/019 60 film-coated tablets EU/1/10/620/004 112 film-coated tablets EU/1/10/620/005 168 film-coated tablets EU/1/10/620/020 180 film-coated tablets EU/1/10/620/006 196 film-coated tablets EU/1/10/620/007 50 x 1 film-coated tablets EU/1/10/620/008 196 (2 x 98) film-coated tablets EU/1/10/620/017 168 (2 x 84) film-coated tablets
Den maksimale daglige dosis er 1.000 mg. 
Maximum daily dose is 1000 mg.
- Hvis De for nylig har haft et hjerteanfald eller har alvorlige kredsløbsproblemer, herunder shock eller vejrtrækningsbesvær. 
depending on how your kidneys are working - if you have recently had a heart attack or have severe circulatory problems, such as ‘shock' or breathing difficulties - if you have liver problems - if you drink alcohol to excess (either every day or only from time to time) - if you are breast-feeding.
I kliniske undersøgelser ændrede sitagliptin ikke farmakokinetikken for metformin, glyburid, simvastatin, rosiglitazon, warfarin eller orale kontraceptiva betydeligt. 
In clinical studies, sitagliptin did not meaningfully alter the pharmacokinetics of metformin, glyburide, simvastatin, rosiglitazone, warfarin, or oral contraceptives, providing in vivo evidence of a low propensity for causing interactions with substrates of CYP3A4, CYP2C8, CYP2C9, and organic cationic transporter (OCT).
HbA1c (%) i 24. uge HbA1c (%) i 26. uge Gennemsnit beregnet ved mindste kvadraters metode justeret for anvendelse af insulin ved besøg 1 (forblandet versus ikkeforblandet [middellangtidsvirkende eller langtidsvirkende]) og baseline-værdi. 
Least squares mean adjusted for insulin use at Visit 1 (pre-mixed vs. non-pre-mixed [intermediate- or long-acting]), and baseline value.
- Hvis De tager anden diabetesmedicin, sulfonylurinstof eller insulin, sammen med Ristfor, da De så kan opleve lavt blodsukker (hypoglykæmi). 
This is sometimes called insulin-dependent diabetes - if you have or have had an allergic reaction to sitagliptin, metformin, or Ristfor (see section 4) - if you are taking a sulphonylurea or insulin, diabetes medicines, together with Ristfor, as you may experience low blood sugar levels (hypoglycaemia).
Er De i tvivl, så spørg lægen eller apotekspersonalet. 
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Placebokorrigeret gennemsnitlig ændring i HbA1c 
Placebo-corrected mean change in HbA1c (%) (95 % CI)
Udseende og pakningsstørrelser 
What Ristfor looks like and contents of the pack
Hvis De har taget for meget Ristfor 
If you take more Ristfor than you should
- Hvis De har dårligt kontrolleret diabetes, der eksempelvis er ledsaget af alvorlig hyperglykæmi (højt blodsukker), kvalme, opkastning, diarré, hurtigt vægttab, laktacidose (se ”Risiko for laktacidose” nedenfor) eller ketoacidose. 
Do not take Ristfor: - if you are allergic to sitagliptin or metformin or any of the other ingredients of this medicine (listed in section 6) - if you have severely reduced kidney function - if you have uncontrolled diabetes, with e.g. severe hyperglycaemia (high blood glucose), nausea, vomiting, diarrhoea, rapid weight loss, lactic acidosis (see “Risk of lactic acidosis” below) or ketoacidosis.
Sitagliptin viste ingen bivirkninger i en præ- og postnatal udviklingsundersøgelse udført med rotter. 
In a pre-/post-natal development study performed in rats sitagliptin showed no adverse effects.
Kontakt lægen for at få yderligere vejledning, hvis noget af ovennævnte gælder for Dem. 
If any of the above apply to you, talk to your doctor for further instructions.
Ikke almindelige (kan berøre op til 1 ud af 100 behandlede): Mavesmerter, diarré, forstoppelse, lavt blodsukker, døsighed. 
Some patients taking metformin have experienced the following side effects after starting sitagliptin: Common (may affect up to 1 in 10 people): low blood sugar, nausea, flatulence, vomiting Uncommon (may affect up to 1 in 100 people): stomach ache, diarrhoea, constipation, drowsiness
Hver filmovertrukken tablet (tablet) indeholder sitagliptinphosphatmonohydrat svarende til 50 mg sitagliptin og 1.000 mg metforminhydrochlorid. 
Each film-coated tablet (tablet) contains sitagliptin phosphate monohydrate equivalent to 50 mg of sitagliptin and 1,000 mg of metformin hydrochloride.
Hver filmovertrukken tablet (tablet) indeholder sitagliptinphosphatmonohydrat svarende til 50 mg sitagliptin og 850 mg metforminhydrochlorid. 
Each film-coated tablet (tablet) contains sitagliptin phosphate monohydrate equivalent to 50 mg of sitagliptin and 850 mg of metformin hydrochloride.
Talcum (E553b) Titandioxid (E171) Rød jernoxid (E172) Sort jernoxid (E172) 
Film coating poly(vinyl alcohol) macrogol 3350 talc (E553b) titanium dioxide (E171) iron oxide red (E172) iron oxide black (E172)
Hver tablet indeholder sitagliptinphosphatmonohydrat svarende til 50 mg sitagliptin og 850 mg metforminhydrochlorid. 
Each tablet contains sitagliptin phosphate monohydrate equivalent to 50 mg of sitagliptin and 850 mg of metformin hydrochloride.
Til patienter, der ikke er tilstrækkeligt kontrolleret på maksimal tolereret dosis af metforminmonoterapi 
For patients inadequately controlled on dual combination therapy with the maximal tolerated dose of metformin and a sulphonylurea
Hver tablet indeholder sitagliptinphosphatmonohydrat svarende til 50 mg sitagliptin og 1.000 mg metforminhydrochlorid. 
Each tablet contains sitagliptin phosphate monohydrate equivalent to 50 mg of sitagliptin and 1,000 mg of metformin hydrochloride.
Ristfor 50 mg/1.000 mg filmovertrukne tabletter sitagliptin/metforminhydrochlorid 
Ristfor 50 mg/1,000 mg film-coated tablets sitagliptin/metformin hydrochloride
Det skal De vide, før De begynder at tage Ristfor Sådan skal De tage Ristfor Bivirkninger 
What Ristfor is and what it is used for What you need to know before you take Ristfor How to take Ristfor
Ristfor 50 mg/850 mg filmovertrukne tabletter Sitagliptin/metforminhydrochlorid 
Ristfor 50 mg/850 mg film-coated tablets sitagliptin/metformin hydrochloride
Ristfor 50 mg/850 mg tabletter sitagliptin/metforminhydrochlorid 
Ristfor 50 mg/850 mg tablets sitagliptin/metformin HCl
Ristfor 50 mg/1000 mg tabletter sitagliptin/metforminhydrochlorid 
Ristfor 50 mg/1,000 mg tablets sitagliptin/metformin HCl
Bulløs pemfigoid 
Uncommon nausea
Ristfor indeholder: 
What Ristfor contains
Flatulens 
Common flatulence
Tel.: +421 2 58282010 dpoc_czechslovak@merck.com 
Slovenská republika Merck Sharp & Dohme, s. r. o. Tel.: +421 2 58282010 dpoc_czechslovak@merck.com
tmax er mellem 3 og 8 timer. 
tmax is between 3 and 8 hours.
Diagnosen skal stilles i henhold til gældende retningslinjer. 
Diagnosis should be made according to current guidelines.
Lægen vil rådgive Dem. 
Your doctor will advise you.
Distributionsvolumen er ca. 10 l/kg. 
The volume of distribution is around 10 l/kg.
Generelt er de observerede bivirkninger milde til moderate. 
In general, the observed side effects are mild to moderate.
Man → Tirs → Ons → Tors → Fre → Lør → Søn 
Mon → Tue → Wed → Thu → Fri → Sat → Sun
I et andet tilfælde med stor overdosis overlevede patienten også og kom sig. 
In another case of a large overdose, the patient also survived and recovered.
Som et resultat heraf er der kun en begrænset mængde data til rådighed, og patienter med disse tilstande skal overvåges nøje. 
As a consequence, only limited data are available and patients with these conditions should be closely supervised.
Effekten af barbiturater og neuroleptika kan blive reduceret. 
The effects of barbiturates and neuroleptics may be reduced.
Den kliniske relevans af disse observationer er ukendt. 
The clinical relevance of these findings is unknown.
Der findes ingen specifik modgift mod forgiftning eller overdosering. 
No specific antidote for intoxication or overdose is available.
Der er en mulig sammenhæng mellem denne akkumulation og den vakuolisation, der observeredes i lunger. 
There is a possible relationship between this accumulation and the vacuolisation observed in lungs.
Uge 1, 2, 3, 4 Dag 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 
Week 1, 2, 3, 4 Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
Ikke kendte (hyppigheden kan ikke fastsættes ud fra forhåndenværende data): 
Not known (frequency cannot be estimated from the available data):
Denne virkning blev kun observeret ved høje doser hos gnavere. 
This effect was only observed at high doses in rodents.
Hukommelsestab ved Alzheimers sygdom skyldes en forstyrrelse af signalstoffer i hjernen. 
Memory loss in Alzheimer's disease is due to a disturbance of message signals in the brain.
Patienten fik symptomatisk behandling og plasmaferese. 
The patient received symptomatic treatment and plasmapheresis.
Behandlingen bør iværksættes og overvåges af en læge med erfaring i diagnosticering og behandling af Alzheimers demens. 
Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer's dementia.
Memantin har en absolut biotilgængelighed på ca. 100%. 
Memantine has an absolute bioavailability of approximately 100%.
EXP {MM/ÅÅÅÅ} 
EXP {MM/YYYY}
Omkring 45% af memantin bindes til plasmaproteiner. 
About 45% of memantine is bound to plasma-proteins.
SYSTEMORGANKLASSE 
SYSTEM ORGAN CLASS
ÆSKE OG MÆRKAT TIL FLASKE 
CARTON AND LABEL FOR BOTTLE
Denne virkning kendes fra andre aktive stoffer med kationiske amfifile egenskaber. 
This effect is known from other active substances with cationic amphiphilic properties.
På grund af den farmakologiske effekt af og virkningsmekanismen for memantin kan følgende interaktioner forekomme: 
Due to the pharmacological effects and the mechanism of action of memantine the following interactions may occur:
I den prospektivt definerede primære analyse opnåedes der ikke statistisk signifikans på det primære effektmål i uge 24. 
In the prospectively defined primary analysis statistical significance was not reached at the primary efficacy endpoint at week 24.
En gang dagligt 
Once daily
GENEREL KLASSIFIKATION FOR UDLEVERING 15. 
GENERAL CLASSIFICATION FOR SUPPLY 15.
Opløsningen skal tages med lidt vand. 
The solution should be taken with a little water.
Psykotiske reaktioner2 
Psychotic reactions2
Det modulerer virkningen af patologisk forhøjede toniske niveauer af glutamat, der kan medføre neuronal dysfunktion. 
It modulates the effects of pathologically elevated tonic levels of glutamate that may lead to neuronal dysfunction.
Oral opløsning 50 ml 
Oral solution 50 ml
2 Enkeltstående tilfælde rapporteret efter markedsføringen. 
2 Isolated cases reported in post-marketing experience.
Visse faktorer, der kan forhøje urin-pH (se under punkt 5.2), kan nødvendiggøre omhyggelig monitorering af patienten. 
Some factors that may raise urine pH (see section 5.2 “Elimination”) may necessitate careful monitoring of the patient.
De kan opleve forøgede symptomer, som beskrevet i punkt 4 “Bivirkninger”. 
You may experience increased symptoms as described in section 4.
I tilfælde af overdosering bør der anvendes symptomatisk behandling. 
In the event of overdose, treatment should be symptomatic.
Tabletterne bør synkes sammen med noget vand. 
The tablets should be swallowed with some water.
Denne dosis vil blive øget hver uge med 5 mg, indtil den anbefalede (vedligeholdelses-) dosis er nået. 
This dose will be increased weekly by 5 mg until the recommended (maintenance) dose is reached.
100 D-60318 Frankfurt/Main Tyskland 
100 D-60318 Frankfurt/Main Germany
Deres læge vil give Dem besked på, om Deres sygdom tillader, at De uden risiko kan køre bil og betjene maskiner. 
Your doctor will tell you whether your illness allows you to drive and to use machines safely.
Dato for første markedsføringstilladelse: 22 november 2012 Dato for seneste genregistrering: {DD måned ÅÅÅÅ} 
Date of first authorisation: 22 Nov 2012 Date of latest renewal: {DD month YYYY}
- de må ikke tage en dobbeltdosis som erstatning for den glemte dosis. 
- Do not take a double dose to make up for a forgotten dose.
Behandlingsskemaet er også angivet på behandlingspakken. 
The treatment scheme is also indicated on the treatment initiation pack.
Da virkningerne hverken er blevet observeret i langtidsstudier hos gnavere eller hos ikke-gnavere, er den kliniske relevans af disse observationer ukendt. 
As the effects have neither been observed in long term studies in rodents nor in non-rodents, the clinical relevance of these findings is unknown.
Hos mennesket er ca. 80% af det cirkulerende memantin-relaterede materiale til stede som modersubstans. 
In man, about 80% of the circulating memantine-related material is present as the parent compound.